Molecular Determinants of Coronary Artery Disease

冠状动脉疾病的分子决定因素

基本信息

  • 批准号:
    7338035
  • 负责人:
  • 金额:
    $ 335.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-02-09 至 2009-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Considerable progress has been made in our understanding of the pathophysiology of coronary artery disease (CAD); however, the genetic and molecular determinants that predispose to enhanced risk for cardiovascular disease remain poorly defined. The primary goal of this Research Program is to identify genetic and molecular determinants that participate in the development of CAD and its major complication - acute myocardial infarction (MI). To achieve this goal, our close-knit, multidisciplinary, and fully integrated team will employ a combination of clinical and translational studies that draw upon our institution's strength in cardiovascular patient care. The Research Program is structured into 4 interrelated Projects and 5 Cores that serve the Projects, including a Clinical Core built around a family based (GeneQuest) and a population based (GeneBank) clinical cohort. The goals of Project 1 are to identify and characterize genes that lead to premature CAD/MI. Preliminary data include the discovery, from a single extended pedigree, of a functional mutation in the MEF2A gene that is linked to autosomal dominantly inherited CAD, and the identification of a locus on chromosome 1 that is linked to premature MI (LOD score >11), from a genome-wide scan of 428 multiplex families with premature CAD. We propose to characterize this specific mutation, assemble more rich pedigrees, and identify additional genes that predispose to CAD/MI. The goals of Project 2 are to identify the genes responsible for the differences in atherosclerosis susceptibility among inbred strains of mice, and to determine if genetic variation in the human orthologs of these genes are associated with CAD. Preliminary data include murine atherosclerosis susceptibility loci identified through an in silico method, and gene array studies that suggest candidate genes within these loci. The goals of Project 3, originating from our novel finding of thrombospondin (THBS) variants associated with MI, are to characterize the cellular, molecular and structural consequences of 2 common variants in THBS-4 and THBS-2; and, the assessment of the consequences of these THBS variants in patients. The goals of Project 4, based upon extensive prior work in myeloperoxidase and NO-derived oxidants linked to atherosclerotic disease, are to investigate the of implications of oxidant stress, reverse cholesterol transport, and newly identified interconnections between these pathways on coronary atherosclerotic progression/regression in patients. The 5 Cores that support these projects are for 1) Administration, 2) Bioinformatics and biostatistics, 3) Gene expression, sequencing and genotyping, 4) Clinical infrastructure, and 5) Clinical research skills and development. The output from our collective work should have a significant impact on prevention, diagnosis and treatment of coronary artery disease in the future.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EDWARD Franklin PLOW其他文献

EDWARD Franklin PLOW的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EDWARD Franklin PLOW', 18)}}的其他基金

Core A- Administrative Core
核心 A- 行政核心
  • 批准号:
    10471909
  • 财政年份:
    2021
  • 资助金额:
    $ 335.36万
  • 项目类别:
Project 1- Role of Kindlins in Blood and Vascular Cell Biology
项目 1 - Kindlins 在血液和血管细胞生物学中的作用
  • 批准号:
    10661631
  • 财政年份:
    2021
  • 资助金额:
    $ 335.36万
  • 项目类别:
Project 1- Role of Kindlins in Blood and Vascular Cell Biology
项目 1 - Kindlins 在血液和血管细胞生物学中的作用
  • 批准号:
    10471912
  • 财政年份:
    2021
  • 资助金额:
    $ 335.36万
  • 项目类别:
Core A- Administrative Core
核心 A- 行政核心
  • 批准号:
    10661621
  • 财政年份:
    2021
  • 资助金额:
    $ 335.36万
  • 项目类别:
Core A- Administrative Core
核心 A- 行政核心
  • 批准号:
    10268694
  • 财政年份:
    2021
  • 资助金额:
    $ 335.36万
  • 项目类别:
Cell Adhesion and Signaling in Blood and Vascular Cells
血液和血管细胞中的细胞粘附和信号传导
  • 批准号:
    10268693
  • 财政年份:
    2021
  • 资助金额:
    $ 335.36万
  • 项目类别:
Project 1- Role of Kindlins in Blood and Vascular Cell Biology
项目 1 - Kindlins 在血液和血管细胞生物学中的作用
  • 批准号:
    10268697
  • 财政年份:
    2021
  • 资助金额:
    $ 335.36万
  • 项目类别:
TSP-4 genetic variants in atherogenesis and angiogenesis
动脉粥样硬化和血管生成中的 TSP-4 遗传变异
  • 批准号:
    8786098
  • 财政年份:
    2013
  • 资助金额:
    $ 335.36万
  • 项目类别:
TSP-4 genetic variants in atherogenesis and angiogenesis
动脉粥样硬化和血管生成中的 TSP-4 遗传变异
  • 批准号:
    8430242
  • 财政年份:
    2013
  • 资助金额:
    $ 335.36万
  • 项目类别:
TSP-4 genetic variants in atherogenesis and angiogenesis
动脉粥样硬化和血管生成中的 TSP-4 遗传变异
  • 批准号:
    8605068
  • 财政年份:
    2013
  • 资助金额:
    $ 335.36万
  • 项目类别:

相似海外基金

Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
  • 批准号:
    24K21101
  • 财政年份:
    2024
  • 资助金额:
    $ 335.36万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The Epigenetic Regulator Prdm16 Controls Smooth Muscle Phenotypic Modulation and Atherosclerosis Risk
表观遗传调节因子 Prdm16 控制平滑肌表型调节和动脉粥样硬化风险
  • 批准号:
    10537602
  • 财政年份:
    2023
  • 资助金额:
    $ 335.36万
  • 项目类别:
Targeted multimodal stimuli-responsive nanogels for atherosclerosis imaging and therapy
用于动脉粥样硬化成像和治疗的靶向多模式刺激响应纳米凝胶
  • 批准号:
    2880683
  • 财政年份:
    2023
  • 资助金额:
    $ 335.36万
  • 项目类别:
    Studentship
Body composition and atherosclerosis-related biomarkers in women with endometriosis
子宫内膜异位症女性的身体成分和动脉粥样硬化相关生物标志物
  • 批准号:
    23K15842
  • 财政年份:
    2023
  • 资助金额:
    $ 335.36万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
2023 Atherosclerosis
2023 动脉粥样硬化
  • 批准号:
    10675221
  • 财政年份:
    2023
  • 资助金额:
    $ 335.36万
  • 项目类别:
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
  • 批准号:
    10652788
  • 财政年份:
    2023
  • 资助金额:
    $ 335.36万
  • 项目类别:
From genotype to phenotype in a GWAS locus: the role of REST in atherosclerosis
GWAS 位点从基因型到表型:REST 在动脉粥样硬化中的作用
  • 批准号:
    10570469
  • 财政年份:
    2023
  • 资助金额:
    $ 335.36万
  • 项目类别:
Alcohol Regulation of Endothelial Plasticity in Atherosclerosis
酒精对动脉粥样硬化内皮可塑性的调节
  • 批准号:
    10585070
  • 财政年份:
    2023
  • 资助金额:
    $ 335.36万
  • 项目类别:
The role of extracellular vesicle-associated MicroRNAs in HIV-associated atherosclerosis
细胞外囊泡相关 MicroRNA 在 HIV 相关动脉粥样硬化中的作用
  • 批准号:
    10619831
  • 财政年份:
    2023
  • 资助金额:
    $ 335.36万
  • 项目类别:
MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS - TOPMED
动脉粥样硬化的多种族研究 - TOPMED
  • 批准号:
    10974007
  • 财政年份:
    2023
  • 资助金额:
    $ 335.36万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了